Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 1.85
DSCO's Cash to Debt is ranked lower than
71% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. DSCO: 1.85 )
Ranked among companies with meaningful Cash to Debt only.
DSCO' s Cash to Debt Range Over the Past 10 Years
Min: 0.42  Med: 4.90 Max: No Debt
Current: 1.85
Equity to Asset 0.34
DSCO's Equity to Asset is ranked lower than
81% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. DSCO: 0.34 )
Ranked among companies with meaningful Equity to Asset only.
DSCO' s Equity to Asset Range Over the Past 10 Years
Min: -0.11  Med: 0.66 Max: 0.93
Current: 0.34
-0.11
0.93
F-Score: 3
Z-Score: -17.04
M-Score: -3.08
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -2722.89
DSCO's Operating margin (%) is ranked lower than
85% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -70.44 vs. DSCO: -2722.89 )
Ranked among companies with meaningful Operating margin (%) only.
DSCO' s Operating margin (%) Range Over the Past 10 Years
Min: -44250  Med: -7841.41 Max: -834.65
Current: -2722.89
-44250
-834.65
Net-margin (%) -3673.88
DSCO's Net-margin (%) is ranked lower than
87% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -65.41 vs. DSCO: -3673.88 )
Ranked among companies with meaningful Net-margin (%) only.
DSCO' s Net-margin (%) Range Over the Past 10 Years
Min: -43958.21  Med: -7627.79 Max: -850.13
Current: -3673.88
-43958.21
-850.13
ROE (%) -393.40
DSCO's ROE (%) is ranked lower than
95% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: -30.71 vs. DSCO: -393.40 )
Ranked among companies with meaningful ROE (%) only.
DSCO' s ROE (%) Range Over the Past 10 Years
Min: -575.17  Med: -199.56 Max: -113.41
Current: -393.4
-575.17
-113.41
ROA (%) -123.84
DSCO's ROA (%) is ranked lower than
88% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. DSCO: -123.84 )
Ranked among companies with meaningful ROA (%) only.
DSCO' s ROA (%) Range Over the Past 10 Years
Min: -172.49  Med: -104.61 Max: -64.4
Current: -123.84
-172.49
-64.4
ROC (Joel Greenblatt) (%) -3366.56
DSCO's ROC (Joel Greenblatt) (%) is ranked lower than
76% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: -343.83 vs. DSCO: -3366.56 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
DSCO' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -2578.49  Med: -878.08 Max: -462.64
Current: -3366.56
-2578.49
-462.64
Revenue Growth (3Y)(%) 8.50
DSCO's Revenue Growth (3Y)(%) is ranked higher than
62% of the 443 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. DSCO: 8.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
DSCO' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -60.10 Max: 220.5
Current: 8.5
0
220.5
EBITDA Growth (3Y)(%) -19.70
DSCO's EBITDA Growth (3Y)(%) is ranked lower than
70% of the 460 Companies
in the Global Biotechnology industry.

( Industry Median: -2.30 vs. DSCO: -19.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
DSCO' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -56.1  Med: -26.05 Max: 22.4
Current: -19.7
-56.1
22.4
EPS Growth (3Y)(%) -17.60
DSCO's EPS Growth (3Y)(%) is ranked lower than
66% of the 467 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. DSCO: -17.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
DSCO' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -61.7  Med: -24.85 Max: 25.5
Current: -17.6
-61.7
25.5
» DSCO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

DSCO Guru Trades in

DSCO Guru Trades in

DSCO Guru Trades in

Q4 2015

DSCO Guru Trades in Q4 2015

Jim Simons 14,700 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with DSCO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.02
DSCO's P/B is ranked higher than
86% of the 1127 Companies
in the Global Biotechnology industry.

( Industry Median: 2.56 vs. DSCO: 1.02 )
Ranked among companies with meaningful P/B only.
DSCO' s P/B Range Over the Past 10 Years
Min: 0.97  Med: 7.79 Max: 66.11
Current: 1.02
0.97
66.11
P/S 9.63
DSCO's P/S is ranked higher than
98% of the 1127 Companies
in the Global Biotechnology industry.

( Industry Median: 8.95 vs. DSCO: 9.63 )
Ranked among companies with meaningful P/S only.
DSCO' s P/S Range Over the Past 10 Years
Min: 9.04  Med: 301.00 Max: 6834.45
Current: 9.63
9.04
6834.45
EV-to-EBIT 0.06
DSCO's EV-to-EBIT is ranked higher than
99% of the 436 Companies
in the Global Biotechnology industry.

( Industry Median: 19.35 vs. DSCO: 0.06 )
Ranked among companies with meaningful EV-to-EBIT only.
DSCO' s EV-to-EBIT Range Over the Past 10 Years
Min: -9.6  Med: -2.00 Max: 0.2
Current: 0.06
-9.6
0.2
EV-to-EBITDA 0.06
DSCO's EV-to-EBITDA is ranked higher than
99% of the 457 Companies
in the Global Biotechnology industry.

( Industry Median: 16.36 vs. DSCO: 0.06 )
Ranked among companies with meaningful EV-to-EBITDA only.
DSCO' s EV-to-EBITDA Range Over the Past 10 Years
Min: -9.8  Med: -2.10 Max: 0.2
Current: 0.06
-9.8
0.2
Current Ratio 4.98
DSCO's Current Ratio is ranked higher than
52% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.62 vs. DSCO: 4.98 )
Ranked among companies with meaningful Current Ratio only.
DSCO' s Current Ratio Range Over the Past 10 Years
Min: 0.84  Med: 4.25 Max: 19
Current: 4.98
0.84
19
Quick Ratio 4.98
DSCO's Quick Ratio is ranked higher than
54% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. DSCO: 4.98 )
Ranked among companies with meaningful Quick Ratio only.
DSCO' s Quick Ratio Range Over the Past 10 Years
Min: 0.84  Med: 3.91 Max: 19
Current: 4.98
0.84
19
Days Inventory 26.19
DSCO's Days Inventory is ranked higher than
88% of the 416 Companies
in the Global Biotechnology industry.

( Industry Median: 126.53 vs. DSCO: 26.19 )
Ranked among companies with meaningful Days Inventory only.
DSCO' s Days Inventory Range Over the Past 10 Years
Min: 9.5  Med: 58.94 Max: 108.37
Current: 26.19
9.5
108.37
Days Payable 429.50
DSCO's Days Payable is ranked higher than
93% of the 400 Companies
in the Global Biotechnology industry.

( Industry Median: 57.67 vs. DSCO: 429.50 )
Ranked among companies with meaningful Days Payable only.
DSCO' s Days Payable Range Over the Past 10 Years
Min: 47.83  Med: 529.76 Max: 1011.69
Current: 429.5
47.83
1011.69

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.57
DSCO's Price/Net Cash is ranked higher than
86% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: 5.77 vs. DSCO: 1.57 )
Ranked among companies with meaningful Price/Net Cash only.
DSCO' s Price/Net Cash Range Over the Past 10 Years
Min: 2.4  Med: 8.17 Max: 172.81
Current: 1.57
2.4
172.81
Price/Net Current Asset Value 1.29
DSCO's Price/Net Current Asset Value is ranked higher than
89% of the 849 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. DSCO: 1.29 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
DSCO' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.98  Med: 7.60 Max: 161.35
Current: 1.29
0.98
161.35
Price/Tangible Book 1.00
DSCO's Price/Tangible Book is ranked higher than
90% of the 1004 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. DSCO: 1.00 )
Ranked among companies with meaningful Price/Tangible Book only.
DSCO' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.95  Med: 7.09 Max: 61.1
Current: 1
0.95
61.1
Price/Median PS Value 0.03
DSCO's Price/Median PS Value is ranked higher than
99% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 0.87 vs. DSCO: 0.03 )
Ranked among companies with meaningful Price/Median PS Value only.
DSCO' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.05  Med: 0.30 Max: 18.26
Current: 0.03
0.05
18.26
Price/Graham Number 0.25
DSCO's Price/Graham Number is ranked lower than
99.99% of the 407 Companies
in the Global Biotechnology industry.

( Industry Median: 2.23 vs. DSCO: 0.25 )
Ranked among companies with meaningful Price/Graham Number only.
DSCO' s Price/Graham Number Range Over the Past 10 Years
Min: 1.04  Med: 1.13 Max: 1.22
Current: 0.25
1.04
1.22
Earnings Yield (Greenblatt) (%) 1464.11
DSCO's Earnings Yield (Greenblatt) (%) is ranked higher than
100% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -7.50 vs. DSCO: 1464.11 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
DSCO' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 436  Med: 1517.90 Max: 4125.1
Current: 1464.11
436
4125.1

More Statistics

Revenue(Mil) $2
EPS $ -8.32
Beta2.22
Short Percentage of Float1.35%
52-Week Range $1.42 - 25.48
Shares Outstanding(Mil)8.00

Analyst Estimate

Dec15
Revenue(Mil)
EPS($) -0.42
EPS without NRI($) -0.42

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:DYBP.Germany,
Discovery Laboratories Inc was incorporated as a Delaware corporation in 1992. The Company is a specialty biotechnology company engaged in creating life-saving products for critical-care patients with respiratory disease and improving the standard of care in pulmonary medicine. Its proprietary drug technology produces a synthetic, peptide-containing surfactant (KL4 surfactant) that is structurally similar to pulmonary surfactant, a substance produced naturally in the lung and essential for normal respiratory function and survival. The Company is developing its KL4 surfactant in liquid, lyophilized and aerosolized dosage forms. IT is also developing novel drug delivery technologies potentially to enable efficient delivery of its aerosolized KL4 surfactant. The Company is initially engaged in improving the management of respiratory distress syndrome (RDS) in premature infants. It has developed a disposable aerosol-conducting airway connector for infants that is intended to simplify the delivery of aerosolized medications and other inhaled therapies to critical-care patients requiring ventilatory support. The Company has exclusive rights to its CAG technology for use with pulmonary surfactants for all respiratory diseases and conditions. In addition, it hold in the U.S. exclusive rights to the CAG technology for use with certain non-surfactant drugs to treat various pediatric and adult respiratory indications in hospitals and other health care institutions. It has also developed a novel, disposable aerosol-conducting airway connector that is intended to simplify the delivery of aerosolized medications, including its aerosolized KL4 surfactant, and inhaled therapies to infants requiring ventilatory support in the NICU and PICU. AEROSURF, AFECTAIR, AFECTAIR DUO, DISCOVERYLABS, SURFAXIN, SURFAXIN LS, and WARMING CRADLE are the Company's registered and common law trademarks. The Company's development, manufacture, distribution, marketing and advertising of drug, device, and combination drug-device products are subject to extensive regulation by federal, state and local governmental authorities in the U.S., including the FDA, and by similar agencies in other countries.
» More Articles for DSCO

Headlines

Articles On GuruFocus.com
Discovery Laboratories Inc. Reports Operating Results (10-Q) Nov 15 2010 
Discovery Laboratories Inc. Reports Operating Results (10-Q/A) Nov 15 2010 
Discovery Laboratories Inc. Reports Operating Results (10-Q) May 10 2010 
Discovery Laboratories Inc. Reports Operating Results (10-Q) Nov 09 2009 
Discovery Laboratories Inc. Reports Operating Results (10-Q) Aug 10 2009 
Discovery Laboratories Inc. Reports Operating Results (10-Q) May 12 2009 

More From Other Websites
DISCOVERY LABORATORIES INC /DE/ Files SEC form 8-K, Unregistered Sale of Equity Securities, Change... Feb 03 2016
Discovery Labs Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Feb 03 2016
Bucks County biopharm firm names new CEO Feb 02 2016
Discovery Labs Announces Appointment of New Chief Executive Officer and Provides an Update on... Feb 01 2016
Discovery Labs Announces Appointment of New Chief Executive Officer and Provides an Update on... Feb 01 2016
Discovery Labs completes reverse stock split Jan 22 2016
Discovery Labs Announces Reverse Stock Split Jan 21 2016
DISCOVERY LABORATORIES INC /DE/ Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change... Jan 21 2016
Discovery Labs Announces Reverse Stock Split Jan 21 2016
[video]4 Stocks Under $10 Making Big Moves Higher Jan 15 2016
Discovery Laboratories Advances Respiratory Disease Drug Dec 30 2015
DISCOVERY LABORATORIES INC /DE/ Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a... Dec 29 2015
Discovery Labs Announces Initiation of AEROSURF® Phase 2b Clinical Trial Dec 29 2015
Discovery Laboratories, Inc. (DSCO): Are Hedge Funds Right About This Stock? Dec 11 2015
Discovery Laboratories, Inc. Earnings Analysis: Q3, 2015 By the Numbers Dec 10 2015
Results of AEROSURF® Phase 2a Clinical Program in Premature Infants 29 to 34 Weeks Gestational Age... Dec 10 2015
Results of AEROSURF® Phase 2a Clinical Program in Premature Infants 29 to 34 Weeks Gestational Age... Dec 10 2015
DISCOVERY LABORATORIES INC /DE/ Financials Dec 08 2015
Discovery Labs Announces Top Line Results of AEROSURF® Phase 2a Clinical Program in Premature... Nov 12 2015
DISCOVERY LABORATORIES INC /DE/ Files SEC form 8-K, Regulation FD Disclosure, Other Events,... Nov 12 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK